Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp239 | Osteoporosis: evaluation and imaging | ECTS2014

Impact of metal artefacts in QCT of the hip caused by a contralateral Gamma type nail: an ex vivo study

Engelke Klaus , Bouler Nicolas , Fuerst Oleg Museyko , Parratte Sebastien , Fuerst Thomas , Pion Francois-Xavier , Champsaur Pierre , Genant Harry , Corroller Thomas Le

Introduction: Gamma type nails are routinely used for the fixation of intertrochanteric fractures of the proximal femur. QCT at the hip is an advanced method that is increasingly being used to estimate BMD and determine the future fracture risk. Yet, implants cause metal artefacts (MA) in CT images, even at the contralateral side due to the high absorption of metal, which may impair BMD accuracy.Methods: Three human cadavers were scanned first without an...

ba0005cabs.oc1.2 | Oral Communications | ECTS2016

Bone and metabolic parameters are associated with overall survival in patients with bone metastases from adenocarcinoma lung cancer: the POUMOS study

Confavreux Cyrille B. , Chambard Lauriane , Ollier Edouard , Brevet Marie , Duboeuf Francois , Rousseau Jean-Charles , Pialat Jean-Baptiste , Wegrzyn Julien , Tescaru Agnes , Szulc Pawel , Carlier Marie-Christine , Girard Nicolas , Clezardin Philippe

Rational: Mortality due to non-small cell lung cancers is the first cause of cancer death in men around the world. Lung adenocarcinoma regularly induces bone metastases responsible for high morbidity and impaired life quality. Overall survival of these patients is poor. Thus we aimed to identify if some bone and metabolic parameters were associated with overall survival.Patients and Methods: POUMOS is a prospective cohort of patients suffering from adeno...

ba0001pp141 | Cancer and bone: basic, translational and clinical | ECTS2013

Therapeutic interest of Imatinib Mesylate in osteosarcoma

Gobin Berengere , Moriceau Gatien , Ory Benjamin , Brion Regis , Redini Francoise , Heymann Dominique

Osteosarcoma is the most common primary malignant bone tumor, characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments points out the importance of exploring new therapeutic ways. Imatinib Mesylate (Glivec, Novartis Pharma), a tyrosine kinase inhibitor, has been originally developed for the treatment of chronic myeloid leukemia. Several studies revealed that Imatinib Mesylate inhibits osteoclast differentiation th...

ba0001pp316 | Osteoporosis: evaluation and imaging | ECTS2013

Cortical and trabecular bone parameters from HR-Pqct images at the Tibia: a local comparison with synchrotron radiation micro-computed tomography

Ostertag Agnes , Peyrin Francoise , Fernandez Sylvie , Laredo Jean-Denis , De Vernejoul Marie-Christine , Chappard Christine

In clinical research protocols, HR-pQCT images (XtremCT Scanco, voxel size: 82 (μm3) are carried out to evaluate trabecular and cortical bone changes induced by osteoporosis and treatments. Micro-computed tomography (μ-CT) has become a standard tool for examination of trabecular and cortical bone in 3D.The purpose of this study is to evaluate the accuracy of cortical and trabecular measurements derived from HR-pQCT images with morpho...

ba0002p31 | (1) | ICCBH2013

Craniofacial consequences of high dose zoledronic acid injections in onco-pediatric patients

Lezot Frederic , Chesneau Julie , Battaglia Severine , Brion Regis , Farges Jean-Christophe , Heymann Dominique , Redini Francoise

Background: High doses of zoledronic acid (ZOL), one of the most potent inhibitors of bone resorption; is currently evaluated in a phase III clinical trial in Europe for the treatment of malignant pediatric primary bone tumors. The impact of such an intensive treatment on the craniofacial skeleton is a critical question in the context of patients with actively growing skeleton; in particular in the light of our previous studies evidencing that endochondral bone formation was t...

ba0002p125 | (1) | ICCBH2013

Growth plate modifications in lysophosphatidic acid LPA1 receptor-invalidated mice

Gennero Isabelle , Laurencin-Dalicieux Sara , Conte-Auriol Francoise , Briand-Mesange Fabienne , Chun Jerold , Salles Jean-Pierre

Objectives: Lysophosphatidic acid (LPA) is a potent lipid growth factor which possess several G protein-coupled receptors LPA1-6. We have recently demonstrated that LPA1 receptor-invalidated mice display abnormal bone development and osteoporosis, suggesting abnormal endochondral ossification. We have here further studied the growth plates of LPA1 receptor-invalidated mice.Methods: We performed a microscopic and immuno-histochemistry analysis of the femo...

ba0002p131 | (1) | ICCBH2013

Ghrelin differentiates human osteoblasts via GHS-R1a receptor

Gennero Isabelle , Barre Ronan , Conte-Auriol Francoise , Beton Nicolas , Salles Jean Pierre

Objectives: Ghrelin is a peptide hormone secreted in the stomach, which stimulates GH release and food intake. It is also known to have an effect on bone metabolism. The ghrelin specific receptor, GHS-R1a, belongs to the G protein-coupled receptors (GPCRs). Its downstream pathway in osteoblasts remains unclear. We attempted to clarify the way by which ghrelin acts on osteoblast differentiation.Methods: We studied two human osteosarcoma cell lines, MG63 a...

ba0003pp93 | Cancer and bone: basic, translational and clinical | ECTS2014

Inhibition of TGF-β signaling pathway blocks the development of osteosarcoma lung metastases

Lamora Audrey , Talbot Julie , Bougras Gwenola , Deley Marie Cecile Le , Heymann Dominique , Redini Francoise , Verrecchia Franck

Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastases are present at diagnosis (survival rate drops to 20% when lung metastases were detected). Because TGF-β has been shown to promote metastases in many solid tumors, we investigated the effects of inhibition of the TGF-β/Smad cascade on osteosarcoma behavior. To this end, two independent procedures, a pharmacological approach ...

ba0005p415 | Osteoporosis: treatment | ECTS2016

rs72658163, a new heterozygous variant in COL1A2 associated with atypical femoral fracture

Funck-Brentano Thomas , Ostertag Agnes , Debiais Francoise , Fardellone Patrice , Collet Corinne , Mornet Etienne , Cohen-Solal Martine

Atypical femoral fractures (AFF) of the subtrochanteric region are rare. Bisphosphonates account to a large extent to their occurrence, however AFF also occur without exposure to bone medication. We here assessed the genetic factors associated with AFF among subtrochanteric fractures. Cases of subtrochanteric or femoral shaft fractures were identified through ICD-10 codes in three French academic centers from 2007 to 2010. Medical records were analyzed by two investigators tha...

ba0006oc19 | (1) | ICCBH2017

Mesenchymal stromal stem cells in pediatric orthopedic oncology, focus on osteosarcoma

Trichet Valerie , Nail Louis-Romee Le , Guiho Romain , Layrolle Pierre , Redini Francoise

Introduction: Conventional therapy of osteosarcoma, a primary malignant bone tumor, includes surgical excision with wide resection, which leads to physical and aesthetic defects. Allografts for reconstruction of bone and joints and adipose tissue autologous grafts for soft tissue defects can be supplemented with mesenchymal stromal/stem cells (MSCs). Additionally MSCs may be used in tumor-targeted cell therapy. However MSCs may have adverse effects on osteosarcoma development,...